secwatch.observer — SEC 8-K summary
======================================

Issuer:     SI-BONE, Inc. (SIBN)
CIK:        0001459839
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001459839-22-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)
-------------------------------------------------------------------

- Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.
- Gross margin 86% vs 89% YoY; operating loss $17.9M vs $13.0M.
- Net loss $18.5M ($0.54 per diluted share) vs $14.0M ($0.42) in Q2 2021.
- Cash $114.4M; long-term borrowings $35.1M; FY2022 revenue guidance reaffirmed at $106-108M.
- FDA clearances for iFuse-TORQ pelvic fractures and iFuse Bedrock Granite; CMS NTAP up to $9,828.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/0001459839-22-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/sibn-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001459839-22-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer